Neurocrine Biosciences, Inc.
NBIX
$128.04
-$0.87-0.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.49% | 11.12% | 21.84% | 24.72% | 30.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.49% | 11.12% | 21.84% | 24.72% | 30.37% |
| Cost of Revenue | 27.61% | 63.21% | 33.49% | 32.33% | 27.34% |
| Gross Profit | 10.77% | -13.83% | 17.23% | 21.34% | 31.99% |
| SG&A Expenses | 18.31% | 13.74% | 37.87% | 14.74% | 9.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.52% | 33.88% | 36.12% | 22.29% | 16.67% |
| Operating Income | -1.56% | -77.49% | -12.84% | 30.88% | 100.95% |
| Income Before Tax | 61.76% | -57.39% | -17.96% | 64.62% | -18.91% |
| Income Tax Expenses | 54.76% | 176.40% | 17.82% | 86.15% | 28.74% |
| Earnings from Continuing Operations | 65.38% | -81.80% | -30.20% | 56.20% | -31.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.38% | -81.80% | -30.20% | 56.20% | -31.94% |
| EBIT | -1.56% | -77.49% | -12.84% | 30.88% | 100.95% |
| EBITDA | -1.48% | -71.93% | -11.47% | 30.40% | 97.20% |
| EPS Basic | 68.41% | -81.79% | -31.31% | 51.26% | -34.10% |
| Normalized Basic EPS | -0.87% | -64.38% | -10.73% | 29.49% | 96.07% |
| EPS Diluted | 68.25% | -81.14% | -30.74% | 51.22% | -33.68% |
| Normalized Diluted EPS | 0.17% | -64.04% | -9.81% | 29.62% | 95.28% |
| Average Basic Shares Outstanding | -1.79% | -0.10% | 1.63% | 3.27% | 3.28% |
| Average Diluted Shares Outstanding | -2.79% | -1.06% | 0.59% | 3.17% | 3.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |